Estrella Immunopharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ (Deficit) Equity
| Additional · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Treasury · Paid-in · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Stock | Capital | Deficit | Deficit | |
| Balance, June 30, 2024 | 36,610,870 | $3,661 | $(354,440) | $24,124,543 | $(19,500,276) | $4,273,488 |
| Issuance of common stock through common stock purchase agreement | 70,000 | 7 | - | 79,484 | - | 79,491 |
| Stock-based compensation | - | - | - | 432,256 | - | 432,256 |
| Purchase of treasury stock | - | - | (214,477) | - | - | (214,477) |
| Net loss | - | - | - | - | (4,427,027) | (4,427,027) |
| Balance, December 31, 2024 | 36,680,870 | 3,668 | (568,917) | 24,636,283 | (23,927,303) | 143,731 |
| Purchase of treasury stock | - | - | (29,462) | - | - | (29,462) |
| Stock-based compensation | - | - | - | 618,974 | - | 618,974 |
| Issuance of common stock for PIPE investment | 1,600,000 | 160 | - | 1,964,051 | - | 1,964,211 |
| Issuance of additional common stock for settlement of subscription agreement | 205,349 | 21 | - | (21) | - | - |
| Net loss | - | - | - | - | (13,063,512) | (13,063,512) |
| Balance, December 31, 2025 | 38,486,219 | $3,849 | $(598,379) | $27,219,287 | $(36,990,815) | $(10,366,058) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.